- Home
- LOCO vs ACIU Comparison
LOCO vs ACIU Comparison
Compare LOCO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- ACIU
- Stock Information
- Founded
- LOCO 1980
- ACIU 2003
- Country
- LOCO United States
- ACIU Switzerland
- Employees
- LOCO N/A
- ACIU N/A
- Industry
- LOCO Restaurants
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- ACIU Health Care
- Exchange
- LOCO Nasdaq
- ACIU Nasdaq
- Market Cap
- LOCO 412.4M
- ACIU 332.4M
- IPO Year
- LOCO 2014
- ACIU 2016
- Fundamental
- Price
- LOCO $11.63
- ACIU $2.68
- Analyst Decision
- LOCO Hold
- ACIU Strong Buy
- Analyst Count
- LOCO 2
- ACIU 2
- Target Price
- LOCO $13.00
- ACIU $12.00
- AVG Volume (30 Days)
- LOCO 210.4K
- ACIU 134.5K
- Earning Date
- LOCO 10-31-2024
- ACIU 11-05-2024
- Dividend Yield
- LOCO N/A
- ACIU N/A
- EPS Growth
- LOCO 0.40
- ACIU N/A
- EPS
- LOCO 0.78
- ACIU N/A
- Revenue
- LOCO $470,971,000.00
- ACIU $48,505,404.00
- Revenue This Year
- LOCO $2.72
- ACIU $85.33
- Revenue Next Year
- LOCO $3.75
- ACIU $80.69
- P/E Ratio
- LOCO $14.87
- ACIU N/A
- Revenue Growth
- LOCO N/A
- ACIU 4097200.00
- 52 Week Low
- LOCO $8.17
- ACIU $2.25
- 52 Week High
- LOCO $14.25
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- LOCO 38.10
- ACIU 27.49
- Support Level
- LOCO $11.54
- ACIU $2.62
- Resistance Level
- LOCO $13.14
- ACIU $3.02
- Average True Range (ATR)
- LOCO 0.40
- ACIU 0.13
- MACD
- LOCO -0.07
- ACIU -0.05
- Stochastic Oscillator
- LOCO 6.79
- ACIU 9.52
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.